COVID pioneer BioNTech: The fall of Germany's pandemic hero

BioNTech, the German biotech company that gained prominence through COVID-19 vaccine development, is now facing challenges including declining vaccine demand, corporate restructuring, and the departure of its founders. The company is attempting to pivot toward cancer treatment trials to establish itself as a major biotech player beyond its initial pandemic success.